Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Hosted on MSN
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...
9don MSN
Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG stands among them. CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is a ...
Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in vivo CRISPR therapy in a phase 1 trial. But the incumbents look set to fight ...
Biotechnology is revolutionizing industries and transforming human health worldwide. Today’s biotech leaders must bridge laboratory breakthroughs with business strategy to bring life-changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback